Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Evidence of Reye’s/Nonaspirin Salicylates Link - Procter & Gamble

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble will continue to support Reye's syndrome warnings for bismuth salicylates, provided that such warnings do not imply the ingredient increases risk of the disease

You may also be interested in...



Attapulgite, Polycarbophil Excluded From OTC Antidiarrheal Final Monograph

Activated attapulgite is reclassified from proposed Category I status to nonmonograph in the 1OTC Antidiarrheal Drug Products final monograph, published in the April 17 Federal Register

Bismuth Subsalicylate “Relieves Travelers’ Diarrhea” Claim Proposed by FDA

Relief of travelers' diarrhea would be included as an indication for bismuth subsalicylate products in the OTC antidiarrheal drug final monograph under a proposed rule published in the 1April 17 Federal Register

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel